Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Short-term Investments (2016 - 2025)

UroGen Pharma (URGN) has disclosed Short-term Investments for 10 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 25.46% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, up 25.46%, and an annual FY2025 reading of $1.3 million, up 25.46% over the prior year.
  • Short-term Investments was $1.3 million for Q4 2025 at UroGen Pharma, roughly flat from $1.3 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $91.9 million in Q1 2025 and bottomed at $812000.0 in Q3 2022.
  • Average Short-term Investments over 5 years is $16.2 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Short-term Investments crashed 98.68% in 2021, then soared 11061.24% in 2025.
  • Year by year, Short-term Investments stood at $1.2 million in 2021, then soared by 3534.26% to $44.6 million in 2022, then tumbled by 98.16% to $821000.0 in 2023, then soared by 31.06% to $1.1 million in 2024, then grew by 25.46% to $1.3 million in 2025.
  • Business Quant data shows Short-term Investments for URGN at $1.3 million in Q4 2025, $1.3 million in Q3 2025, and $64.0 million in Q2 2025.